Ethics and stem cell therapeutics for cardiovascular disease

被引:4
|
作者
Sugarman, Jeremy
机构
[1] Johns Hopkins Univ, Berman Inst Bioeth, Dept Med, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USA
关键词
D O I
10.1016/j.pcad.2007.02.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As research on stem cell therapeutics for the treatment of cardiovascular diseases in adults is being planned and conducted it is essential to address the ethical issues associated with it. The considerable attention that is currently focused on the ethical issues associated with stem cell research as well as the acute clinical situations sometimes encountered when treating cardiovascular disease, underscore the need for explicit attention to the ethical aspects of this research. In this article, I survey some of the key ethical considerations regarding research involving stem cell therapeutics for cardiovascular diseases including: (1) the standard ethical considerations for translational and clinical research and mechanisms of ethical oversight of them; (2) additional oversight related to stem cell research; (3) considerations for obtaining informed consent for this research and in selecting individual human subjects to participate in it; (4) concerns related to justice that may manifest themselves with respect to which research endeavors move forward and (5) conflicts of interest in research and their potential relationship to research integrity. © 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [31] The Promise and Perils of Stem Cell Therapeutics
    Daley, George Q.
    CELL STEM CELL, 2012, 10 (06) : 740 - 749
  • [32] Leukotriene modifiers as potential therapeutics for cardiovascular disease
    Funk, CD
    NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (08) : 664 - 672
  • [33] MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
    van Rooij, Eva
    Olson, Eric N.
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (11) : 860 - 872
  • [34] Novel hydrogen sulfide therapeutics for cardiovascular disease
    Lefer, David J.
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2015, 47 : S9 - S9
  • [35] Pathophysiology and Therapeutics of Cardiovascular Disease in Metabolic Syndrome
    Wang, Yabin
    Yu, Qiujun
    Chen, Yundai
    Cao, Feng
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (27) : 4799 - 4805
  • [36] RNA-based therapeutics in cardiovascular disease
    Tan Phat Pham
    Kremer, Veerle
    Boon, Reinier A.
    CURRENT OPINION IN CARDIOLOGY, 2020, 35 (03) : 191 - 198
  • [37] The Potential of RNA Therapeutics in Treating Cardiovascular Disease
    Mainkar, Gayatri
    Ghiringhelli, Matteo
    Zangi, Lior
    DRUGS, 2025,
  • [38] Inflammation and cardiovascular disease: From mechanisms to therapeutics
    Alfaddagh, Abdulhamied
    Martin, Seth S.
    Leucker, Thorsten M.
    Michos, Erin D.
    Blaha, Michael J.
    Lowenstein, Charles J.
    Jones, Steven R.
    Toth, Peter P.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 4
  • [39] Copper homeostasis and cuproptosis in cardiovascular disease therapeutics
    Yang, Lifang
    Yang, Pingping
    Lip, Gregory Y. H.
    Ren, Jun
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2023, 44 (09) : 573 - 585
  • [40] MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
    Eva van Rooij
    Eric N. Olson
    Nature Reviews Drug Discovery, 2012, 11 : 860 - 872